European Archives - Page 646 of 1125 - European Medical Journal

Cardiology CP

Profiling the Discordant Visceral Adipose Tissue–Ectopic Liver Fat Phenotype: Results from the Dallas Heart Study

The accumulation of visceral adipose tissue (VAT) and ectopic liver fat (ELF) generally parallel each other, but a proportion of individuals have discordant fat deposition…

EMJ Podcast: Patient's-Eye View

Jonathan chats to JR Rizzo and Dr Mahya Beheshti, physician-scientists, NY University Langone Health Center, about visual disabilities.

Drugs: it does exactly what it says on the label

Labelling is the vessel through which vital instructions and information about products are communicated to end-users, and in the pharmaceutical industry, medical affairs are entrusted with safeguarding these products from misuse, by balancing scientific accuracy with conciseness and coherence.

Launching the Future of Technology in 3...2...1...

Innovative technology has changed the game in pharma, from AI-powered marketing campaigns to DNA sequencing tools. When this technology is combined with creative thinking, the potential for success is vast. It is critical for pharma to marry creativity with technology as they drive towards a patient-centric future

Almirall’s Francesca Wuttke on the value of digital innovation for patients

Francesca Wuttke, Chief Digital Officer, Almirall, shares her thoughts on how digital transformation, motivation and innovation can change patients’ lives for the better.

Raising the Voices of Rare Disease

Rare diseases are complex conditions, but these patients are highly educated and determined, using platforms such as social media to make strides towards improving knowledge. It is vital that medical affairs executives consult these empowered, expert patients as they uncover unmet needs and think beyond the medication.

EMJ Oncology 8 [Supplement 2] 2020

Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer

MONARCH 2 was a global, randomised, double-blind, Phase III study of abemaciclib or placebo in combination with fulvestrant in premenopausal…

EMJ Oncology 8 [Supplement 2] 2020

Latest Developments in Advanced Breast Cancer Treatment: A Discussion with Two Key Opinion Leaders about the CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib

The introduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the treatment of advanced breast cancer (ABC; inoperable locally advanced…

EMJ Oncology 8 [Supplement 2] 2020

EMJ Oncology 8 [Supplement 2] 2020

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy (ET) are considered the standard-of-care treatment for patients…

Virtual or Face-to-Face in the Post COVID-19 World?

Niccolo Machiavelli and Winston Churchill have both been credited with the advice: “Never waste the opportunity offered by a good crisis.” It would be…